title: Application of the Gyrolab™ platform to ligand-binding assays: a user's perspective.
abstract: In many areas of drug discovery and development, scientists are in a constant search for methods and platforms to reduce assay time and cost. The Gyrolab™ microfluidics platform that we describe here promises to deliver faster ligand-binding assays with lower reagent and sample consumption, while maintaining good accuracy and precision. Due to its limited track record, we evaluated its performance on assays currently used to support pharmacokinetic and immunogenicity studies, and detection of host cell protein impurities in samples from biotechnology processes. This article summarizes our preliminary conclusions about the utility of the Gyrolab microfluidics platform from Gyros AB.
authors.affiliation: Bristol-Myers Squibb, Route 206 & Province Line Rd, Princeton, NJ, USA. johanna.mora@bms.com
authors.forename: Johanna R
authors.initials: JR
authors.lastname: Mora
authors.forename: Linda
authors.initials: L
authors.lastname: Obenauer-Kutner
authors.forename: Vimal
authors.initials: V
authors.lastname: Vimal Patel
mesh_terms: D055808:Drug Discovery / Q000295:instrumentation*; D004777:Environment; D057166:High-Throughput Screening Assays; D008024:Ligands; D046210:Microfluidic Analytical Techniques / Q000379:methods*; D011485:Protein Binding; D012984:Software
chemical_list: D008024:Ligands